NICE rec­om­mends Pfiz­er's mi­graine drug for use in the UK, with some re­stric­tions

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) is rec­om­mend­ing Pfiz­er’s oral mi­graine drug rimegepant, known com­mer­cial­ly in the US as Nurtec and brand­ed in Eu­rope as Vy­du­ra. How­ev­er, there are a few re­stric­tions at play.

The pub­lic health body is rec­om­mend­ing the drug, orig­i­nal­ly made by Bio­Haven be­fore Pfiz­er’s $11.6 bil­lion ac­qui­si­tion of the com­pa­ny an­nounced last May — but on­ly for those with at least four mi­graine at­tacks a month, and no more than 15 in the same times­pan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER